Nature's Sunshine Products Inc. (NATR)
NATR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/275053/000162828026016540/0001628280-26-016540-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NATR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000275053 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | UT |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $480.1M |
| Net income | $19.5M |
| Operating income | $24.7M |
| Net margin | 4.1% |
| Operating margin | 5.2% |
| Revenue growth | +5.7% |
| Cash | $93.9M |
| Total assets | $261.1M |
| P/E (computed) | 9.4× |
| P/S (computed) | 0.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $89.4M cash; operating cash flow $4.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 17,328,776 (2026-10-23); 17,495,563 a year earlier; 19,075,041 three years earlier. | Cover page 2026-10-23 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Salt Lake City, Utah, United States | PCAOB Form AP 2026-03-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $2.6M, sold $2.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $116.6M | $1.9M | $10.8M | $89.4M | No debt tags | $480.3M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $117.0M | $3.5M | $835K | $82.5M | No debt tags | $492.0M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $122.9M | $5.1M | -$1.8M | $87.6M | No debt tags | $489.8M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $123.8M | $4.1M | $9.9M | $93.9M | No debt tags | $480.1M | 10-K 2026-03-10 |
| Q3 2025 2025-09-30 | $128.3M | $5.3M | $18.5M | $95.6M | No debt tags | $474.5M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $114.8M | $5.3M | $4.3M | $81.3M | No debt tags | $460.8M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $113.2M | $4.7M | $2.6M | $86.5M | No debt tags | $456.6M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $118.2M | -$321K | $12.2M | $84.7M | No debt tags | $454.4M | 10-K 2026-03-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-06-27 |
| Latest annual report | 10-K | 2026-03-10 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-20 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.7% |
| 1 month | -18.8% |
| 3 months | -32.3% |
| Year to date | -52.0% |
| 1 year | -50.0% |
| From 52-week high | -62.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RNAC | Cartesian Therapeutics Inc. | $6.08 | -4.25% | $185.5M |
| SLGL | Sol-Gel Technologies Ltd. | $54.96 | -0.29% | $179.9M |
| WHWK | Whitehawk Therapeutics Inc. | $3.01 | -1.63% | $177.6M |
| KRRO | Korro Bio Inc. | $12.71 | -6.61% | $174.5M |
| IFRX | InflaRx N.V. | $1.18 | +0.85% | $173.9M |
| TRDA | Entrada Therapeutics Inc. | $5.00 | -1.77% | $195.8M |
| NGEN | NervGen Pharma Corp. | $1.82 | -3.19% | $195.9M |
| KROS | Keros Therapeutics Inc. | $10.03 | -2.62% | $196.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier